Peer-Reviewed Papers

Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist

GPCR Target: S1p2, S1p3, S1p4

Authors: Selkirk JV, et al.

Journal: Front. Pharmacol. 13:892097. doi: 10.3389/fphar.2022.892097

Year Published: 2022

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

GPCR Target: LPA5

Authors: Zhang D, et al.

Journal: Eur J Med Chem. 2022 Dec 5;243:114741. doi: 10.1016/j.ejmech.2022.114741

Year Published: 2022

In vitro pharmacodynamic studies of IDG-16177, a Potent GPR40 agonist, for the Treatment of Type 2 Diabetes

GPCR Target: GPR40

Authors: Jongmin Yoon, et al.

Journal: Diabetes 1 June 2021; 70 (Supplement_1): 122–LB. 

Year Published: 2021

Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy

GPCR Target: Membranes isolated from CHO-K1 cells stably expressing human KORs (cat. no. MC1351-1a), MULTISCREENᵀᴹ β-arrestin-2 recruitment assay

Authors: Schrader, T. O., et al.

Journal: ACS Chemical Neuroscience, 15(3), 685–698. 

Year Published: 2024

A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates

Authors: Rady, B., et al.

Journal: Frontiers in Endocrinology, 13. 

Year Published: 2022

Interested In Receiving The Latest Multispan Insights?

Sign Up For Our Newsletter